Get the Stockscreener App
1.55
0.98%
0.015
After Hours:
1.56
0.01
+0.65%
Repare Therapeutics Inc stock is traded at $1.55, with a volume of 29,326.
It is up +0.98% in the last 24 hours and up +3.33% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$1.535
Open:
$1.53
24h Volume:
29,326
Relative Volume:
0.11
Market Cap:
$66.59M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.6951
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
-0.64%
1M Performance:
+3.33%
6M Performance:
+20.16%
1Y Performance:
-48.50%
1-Day Range:
$1.53
$1.58
1-Week Range:
$1.52
$1.59
52-Week Range:
$0.89
$4.0695
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.55 | 66.16M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Bollinger Bands Show Potential Breakout in Repare Therapeutics Inc.Market Sentiment Review & Community Shared Stock Ideas - 선데이타임즈
What earnings revisions data tells us about Repare Therapeutics Inc.July 2025 PreEarnings & Reliable Intraday Trade Alerts - Newser
What MACD and RSI say about Repare Therapeutics Inc.July 2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Newser
Using RSI to spot recovery in Repare Therapeutics Inc.Quarterly Profit Report & Free Safe Capital Growth Stock Tips - Newser
Analyzing drawdowns of Repare Therapeutics Inc. with statistical toolsWeekly Stock Recap & Consistent Growth Equity Picks - Newser
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Institutional scanner results for Repare Therapeutics Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
Predicting Repare Therapeutics Inc. trend using moving averagesMarket Volume Report & Detailed Earnings Play Strategies - Newser
Will Repare Therapeutics Inc. benefit from macro trendsPortfolio Update Report & Safe Capital Investment Plans - Newser
Backtesting results for Repare Therapeutics Inc. trading strategiesTrade Risk Assessment & Proven Capital Preservation Methods - Newser
Automated trading signals detected on Repare Therapeutics Inc.Market Trend Report & Weekly Stock Breakout Alerts - Newser
Repare Therapeutics Inc. stock trendline breakdownJuly 2025 Volume & Reliable Price Breakout Alerts - Newser
Is Repare Therapeutics Inc. still worth holding after the dipWeekly Trend Summary & Community Consensus Stock Picks - Newser
Repare Therapeutics (NASDAQ:RPTX) Announces Earnings Results - MarketBeat
Will Repare Therapeutics Inc. Bounce From 52 Week Low2025 Big Picture & Weekly Market Pulse Alerts - beatles.ru
Repare Therapeutics (NASDAQ:RPTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Candlestick Reversal Detected on Repare Therapeutics Inc.’s ChartScalable Portfolio Growth Suggestions Released - 선데이타임즈
Using portfolio simulators with Repare Therapeutics Inc. includedSafe Investment Ideas with Growth Upside - Newser
Repare Therapeutics (NASDAQ:RPTX) Raised to Hold at Wall Street Zen - Defense World
Is Repare Therapeutics Inc. forming a reversal patternFree Market Surge Signal for Swing Traders - Newser
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSafe Momentum Strategy With Trend Analysis - Newser
Repare Therapeutics Q2 2025 Earnings: EPS Beats Estimates, Revenue Surpasses Expectations - AInvest
Repare Therapeutics Inc (RPTX) Q2 2025 Earnings: EPS of -$0.39 B - GuruFocus
Analyzing recovery setups for Repare Therapeutics Inc. investorsFree Smart Trend Trading with Weekly Signals - Newser
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves - TipRanks
Repare Therapeutics Reports Q2 Earnings: Strategic Moves and Upcoming Data Releases - AInvest
Repare Therapeutics Announces Licensing Deal and Strategic Updates - The Globe and Mail
Repare 2025 Q2 Earnings Strong Improvement as Net Loss Narrows 51.8% - AInvest
Repare Therapeutics Cuts Losses And Snags New Licensing Deals - Finimize
Repare Therapeutics Narrows Losses And Seeks New Paths Forward - Finimize
Repare (RPTX) Q2 Loss Narrows 52% - AOL.com
Repare Therapeutics' Strategic Shift and Milestone-Driven Outlook - AInvest
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year - TipRanks
Repare Therapeutics Inc. SEC 10-Q Report - TradingView
Repare Therapeutics Q2 net loss narrows to $16.7 mln - MarketScreener
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | RPTX Stock News - GuruFocus
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repare Therapeutics Inc Stock (RPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 12 '25 |
Sale |
1.14 |
5,611 |
6,397 |
80,297 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 12 '25 |
Sale |
1.14 |
6,884 |
7,848 |
54,786 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 12 '25 |
Sale |
1.14 |
21,179 |
24,144 |
124,394 |
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):